Abstract:Background CD47,knownasintegrin-associatedreceptorprotein,isover-expressed onnon-small-celllungcancer(NSCLC)cells.Itcaninteractwithsignalregulatory protein-a(SIRPa)andinhibitmacrophagephagocytosis.Autophagy,akeyingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by targeting both CD47 and autophagy. Background ClusterofDifferentiation(CD47),knownasintegrin-associatedreceptor protein,isover-expressedonnon-small-celllungcancer(NSCLC)cells.Itcaninteract withsignalregulatoryprotein-alpha(SIRPa)andinhibitmacrophagephagocytosis. Autophagy, a key ingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by blocking both CD47 and autophagy. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to target CD47onNSCLCcells.Threestandardtechniquesincludingconfocalmicroscope, transmission electron microscope and western blots were used to detect the autophagy in NSCLC cells after CD47 blockade. LDH-release and CFSE staining assay were appliedtodetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy. NSCLC xenograft models were established in BALB/c nude mice to investigate the anti- tumoreffectoftargetingbothCD47andautophagyinNSCLC. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to block CD47onNSCLCcells.Threestandardtechniquesincludingtransmissionelectron microscope, confocal microscope and western blot were used to detect autophagy in NSCLCcellsafterCD47blockade.LDH-releaseandCFSEstainingassaywereapplied todetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy.NSCLC xenograft models were established in BALB/c nude mice to investigate the anti-tumor effectofblockingbothCD47andautophagyinNSCLC. Results WefoundthatblockingCD47couldincreasethephagocytosisandcytotoxicity ofmacrophageagainstNSCLCcells.Duringthisprocess,autophagywastriggered, which was characterized by the three main stages ofautophagic fluxincluding: formation and accumulation ofautophagosomes, fusion ofautophagosomes into lysosomesanddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedcytotoxicity,whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitpotentanti-NSCLCefficacyinvivo. Results WefoundthatblockingCD47couldincreasethephagocytosisofmacrophage against NSCLC cells. During this process, autophagy was triggered, which was characterized by the three main stages ofautophagic fluxincluding: formation andaccumulationofautophagosomes,fusionofautophagosomesintolysosomes anddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedphagocytosis, whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitenhancedanti-NSCLCefficacyinvivo. Conclusions We demonstrated that autophagy was induced in NSCLC cells after CD47 blockade,whileinhibitionofautophagycouldsignificantlyenhancetheanti-tumor efficacyofCD47blockadeinNSCLCs.Ourdataelucidatedthecriticalroleofautophagy inCD47abolishment-basedNSCLStherapyandhighlightedthepotentialapproachfor thetreatmentofNSCLCbyblockingautophagyandCD47. Legal entity responsible for the study N/A Funding the National Natural Science Foundation ofChina (81573332) Disclosure All authors have declared no conflicts ofinterest.

Facilitating cholangiocarcinoma inhibition by targeting CD47

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

399P Blocking CD47 and Autophagy for the Therapy of Non-Small-cell Lung Cancer

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Anti-CD47 Antibody Enhances the Efficacy of Chemotherapy in Patients with Gastric Cancer Liver Metastasis

Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells

Anti-Cd47 Antibody Suppresses Tumour Growth and Augments the Effect of Chemotherapy Treatment in Hepatocellular Carcinoma

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

Deciphering the role of CD47 in cancer immunotherapy

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer

Cd47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small-Cell Lung Cancer

CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.

Blocking CD47 Promotes Antitumour Immunity Through CD103+ Dendritic Cell-Nk Cell Axis in Murine Hepatocellular Carcinoma Model.

Role of CD47 in tumor immunity: a potential target for combination therapy

Characterization of Cluster of Differentiationï¿½47 Expression and Its Potential As a Therapeutic Target in Esophageal Squamous Cell Cancer

Combined Strategies for Effective Cancer Immunotherapy with a Novel Anti-Cd47 Monoclonal Antibody

Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment